eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2018
vol. 35
 
Share:
Share:
Letter to the Editor

Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia

Alicja Adaszewska
,
Norito Ishii
,
Jadwiga Dwilewicz-Trojaczek
,
Katarzyna Woźniak
,
Takashi Hashimoto
,
Cezary Kowalewski

Adv Dermatol Allergol 2018; XXXV (1): 113-115
Online publish date: 2018/02/20
Article file
- Paraneoplastic.pdf  [0.18 MB]
Get citation
 
 
Paraneoplastic pemphigus (PNP) is an autoimmune blistering disorder coexisting with certain neoplasms, most commonly non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and Castleman’s disease [1]. The clinical presentation of PNP consists of painful mucosal erosions, polymorphic cutaneous lesions and systemic involvement. The PNP is characterized by various autoantibodies directed mainly to desmosomal proteins, particularly various plakin family proteins [2]. Recently the 170 kDa 2-macroglobulin-like protein 1 was identified as another PNP antigen [3]. In addition, novel ELISA of mammalian recombinant proteins (RP)s detected autoantibodies to desmocollins 1 (Dsc1) to Dsc3 in 67% of PNP cases [4]. Herein, we report an unusual case of PNP associated with CLL, mediated by antibodies against Dsc3.
In July 2013, a 50-year-old man was admitted to our department with a 6-week history of painful erosions in the oral cavity (Figure 1 A) and significant weight loss (6 kg within 1 month). Direct immunofluorescence (IF) of oral mucosal biopsy and indirect IF of monkey esophagus and human skin showed negative results. The diagnosis of Stevens-Johnson syndrome was made and the patient was treated with prednisolone 40 mg/day and acyclovir 400 mg/day for 1 month with no improvement. After systemic corticosteroids started the patient developed vegetating oral mucosal lesions (Figure 1 B). However, repeated direct IF for oral mucosal lesions remained negative.
Five weeks later the patient presented extensive erosive lesions both in the oral and on the genital mucosa (Figure 1 C). Subsequently, the patient developed disseminated vesicular skin lesions on the trunk and the upper extremities and damaged finger nails (Figure 1 D). A blood test performed at that time disclosed leukocytosis of 20,000 U/l with lymphocytosis. The immunopathological studies were repeated. Direct IF of perilesional skin showed IgG and C3 deposits both on keratinocyte cell surfaces and linearly along the epidermal basement membrane zone (BMZ) (Figure 2 A). Indirect IF of normal human skin, monkey esophagus and guinea pig disclosed circulating IgG anti-cell surface antibodies. Indirect IF of rat bladder also showed positive reaction with transitional epithelia (Figure 2 B). However, indirect IF of 1 M NaCl-split normal human skin showed negative results. Immunoblot (IB) studies were performed using a battery of antigen sources. mmunoblot of normal human epidermal extract was positive for the 210 kDa envoplakin and 190 kDa periplakin, but negative for the 130 kDa desmoglein 3 (Dsg3) and the 160 kDa Dsg1, BP230 and BP180 (Figure 2 C). There was no positive reaction in IB studies of RPs of both NC16a and C-terminal domains of BP180, concentrated culture supernatant of HaCaT cells, normal human dermal extract or purified human laminin-332 (Figure 2 C). Commercially available ELISAs (MBL, Nagoy, Japan) showed a positive reaction with Dsg3 (index value 53.67, cut-off < 14) but not with Dsg1. Novel ELISAs using mammalian RPs of Dsc1-3 [4] detected IgG antibodies to Dsc3 (OD 1.17, cut-off < 0.120), but not to Dsc1 or Dsc2. Trepan biopsy led to the diagnosis of CLL. From these findings, the case was diagnosed as PNP associated with CLL. Pulse therapy consisting of intravenous rituximab (375 mg/m2), cyclophosphamide 1400 mg/day and dexamethasone 12 mg/day was initiated. Between administrations of chemotherapy at 1-month intervals, prednisolone 30 mg/day was given. One month after the first pulse of chemotherapy, skin and mucous lesions significantly improved, whereas CLL came into remission after eight pulses of chemotherapy.
The diagnosis of PNP is often challenging since skin manifestations are initially diverse, resembling erythema multiforme, Stevens-Johnson syndrome or lichenoid disorders. Deposition of IgG and C3 both to the epithelial cell surfaces and along the BMZ in direct IF of skin or mucosal biopsies is characteristic for PNP [5]. Herein, we report a case of PNP associated with CLL, which initially presented severe oral vegetating erosions with repeated negative results of direct and indirect IF. It is likely that Stevens-Johnson syndrome preceded in this case, as reported in patients with other autoimmune bullous diseases [6]. However, it may also be possible that, at the initial phase, our patient produced antibodies exclusively against Dsc3, which were difficult to be detected by routine direct IF, indirect IF and IB studies. Later, anti-Dsc3 antibodies were detected by novel ELISAs of Dsc1-3 RPs. The Dsc ELISA gave a new insight into the pathogenesis of PNP, since 67% of PNP patients showed antibodies against Dsc1-3 [4]. In addition, anti-Dsc3 antibodies have been reported to be responsible for oral lesions, particularly in cases without anti-Dsg3 antibodies [7].
In the past, immunoprecipitation was used for the diagnosis of PNP [1]. However, due to radioisotope use limitations, a combination of IB and indirect IF on a rat bladder is suggested to be equally sensitive for the diagnosis of PNP [5]. This diagnostic method was performed and proved useful in this study. Since anti-Dsc antibodies are present in the majority of PNP patients and may precede the production of other anti-desmosomal antibodies, novel ELISAs of Dsc1-3 should be added to the panel of laboratory tests for rapid diagnosis of PNP.

Conflict of interest

The authors declare no conflict of interest.

References

1. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-35.
2. Schepens I, Jaunin F, Begre N et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010; 5: e12250.
3. Hashimoto T. Production of numerous autoantibodies in paraneoplastic pemphigus. Br J Dermatol 2015; 172: 849-50.
4. Ishii N, Teye K, Fukuda S, et al. Anti-desmocollin autoantibodies in non-classical pemphigus. Br J Dermatol 2015; 173: 59-68.
5. Poot AM, Diercks GF, Kramer D, et. al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013; 169: 1016-24.
6. Wozniak K, Kowalewski C, Hashimoto T, et al. Penicillin-induced anti-p200 pemphigoid: an unusual morphology. Acta Derm Venereol 2006; 86: 443-6.
7. Mao X, Nagler AR, Farber SA, et al. Autoimmunity to desmocollin 3 in pemphigus vulgaris. Am J Pathol 2010; 177: 2724-30.
Copyright: © 2018 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.